Fibroadenoma
A benign fibroepithelial breast lesion, usually presenting in adolescents or young adults as a smooth, firm, mobile lump; diagnosis depends on concordant clinical and imaging assessment, with biopsy or excision when the pattern is atypical.
In a nutshell
Fibroadenoma is a benign fibroepithelial breast lesion, usually a smooth, firm, mobile lump in an adolescent or young adult. Use the age- and feature-appropriate breast assessment pathway: a classic lesion under 25 may not need biopsy, but enlarging, large, complex, atypical or discordant lesions need tissue or specialist review. Confirmed asymptomatic fibroadenomas usually need reassurance rather than surgery; the key safety differential is phyllodes tumour.
Classic presentation
An adolescent or young adult has a smooth, firm, painless, highly mobile breast lump with normal skin, nipple and axillary examination.
Key points
- A fibroadenoma is a benign biphasic fibroepithelial lesion and may enlarge during pregnancy or other hormonal states.
- NICE NG12: suspected cancer referral for an unexplained breast lump at age 30 or over; consider non-urgent referral under age 30, with clinical judgement for suspicious features.
- Under 25, a classic fibroadenoma may not need biopsy if clinical and ultrasound findings are confidently concordant.
- Large, rapidly growing, complex, atypical or discordant lesions need core biopsy, specialist MDT review or excision.
- Most confirmed asymptomatic fibroadenomas need no treatment or routine follow-up.
- Vacuum-assisted excision or open excision can be considered for selected symptomatic, giant, complex or patient-preferred lesions.
- A rapidly growing fibroepithelial mass may be a phyllodes tumour; do not provide routine fibroadenoma reassurance until the diagnosis is secure.
First-line investigation
Age-appropriate breast assessment, usually ultrasound in younger people, with core biopsy when the lesion is atypical, growing, large or discordant.
Management
Identify suspicious breast features
Confirm concordant benignity
Reassure and safety-net
Remove or reclassify selected lesions
Review change rather than schedule routine surveillance
Exam traps
- Mobility is reassuring but does not replace appropriate breast assessment.
- A classic lesion under 25 may not need biopsy, but a growing or atypical lesion does.
- Do not label a rapidly enlarging fibroepithelial mass as a fibroadenoma without considering phyllodes tumour.
- Do not excise every fibroadenoma; most confirmed asymptomatic lesions need no treatment.
- A benign previous biopsy does not mean a later enlarging or changing lesion can be ignored.
Illustrations
Key sources
- NICE HTG449: High-intensity focused ultrasound for symptomatic breast fibroadenoma (NICE health technology guidance summarising diagnosis and treatment options for fibroadenoma, including conservative management, surgery and vacuum-assisted removal; published 13 September 2017.)Updated 13 Sept 2017
- NHS: Fibroadenoma (NHS information on diagnosis, age-related ultrasound and biopsy use, conservative management, excision, vacuum-assisted excision and follow-up; page last reviewed January 2024.)Updated 1 Jan 2024
- NICE NG12: Suspected cancer: recognition and referral (Current NICE breast referral thresholds for unexplained breast lumps, nipple and skin changes and axillary lumps; last updated 15 April 2026.)Updated 15 Apr 2026
- Breast Cancer Now: Fibroadenoma (UK patient information on features, diagnostic biopsy, benign and complex fibroadenoma, phyllodes tumour safety-netting and treatment choices; 2025 edition.)Updated 1 Jan 2025
- NICE HTG80: Interstitial laser therapy for fibroadenomas of the breast (NICE health technology guidance describing conservative management and surgical or minimally invasive removal when fibroadenomas persist, grow or cause concern; published 22 June 2005.)Updated 22 Jun 2005
This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.

